 |
| |
| Mar-01-18 | Reiterated |
H.C. Wainwright |
Buy |
$6 → $7.50 |
|
| Jan-17-18 | Downgrade |
Maxim Group |
Buy → Hold |
|
|
| Oct-09-17 | Initiated |
H.C. Wainwright |
Buy |
$6 |
|
| Apr-27-17 | Initiated |
Laidlaw |
Buy |
$10 |
|
| Jul-01-15 | Upgrade |
Piper Jaffray |
Neutral → Overweight |
|
|
| May-05-15 | Initiated |
H.C. Wainwright |
Buy |
$6 |
|
|
|
| Apr-01-20 07:32AM | Edited Transcript of ONTX earnings conference call or presentation 24-Mar-20 8:30pm GMT Thomson Reuters StreetEvents |
| Mar-24-20 04:05PM | Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial Results GlobeNewswire +15.58% |
| Mar-18-20 08:00AM | Onconova Therapeutics to Provide Corporate Update and Full Year 2019 Financial Results GlobeNewswire |
| Mar-13-20 09:46AM | Will Onconova Therapeutics Continue to Surge Higher? Zacks |
| Mar-02-20 09:54AM | Onconova (ONTX) to Report Q4 Earnings: What's in Store? Zacks +6.33% |
| Feb-21-20 10:12AM | The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis Zacks |
| Feb-20-20 08:45AM | Onconova Therapeutics, Inc. (ONTX) Shares March Higher, Can It Continue? Zacks |
| 07:03AM | US Dollar Flexes Muscles Against Other Currencies: 5 Winners Zacks |
| Feb-19-20 11:19AM | The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics Zacks +8.06% |
| Feb-18-20 10:06AM | Coronavirus to Hit Apple Sales: Invest in Domestic Producers Zacks -6.60% |
| 08:00AM | Onconova Therapeutics Announces Participation in Two Upcoming International Conferences GlobeNewswire |
| Feb-10-20 08:00AM | Onconova Therapeutics to Present Update at Noble Capital Markets Sixteenth Annual Investor Conference in Hollywood, FL GlobeNewswire +22.45% |
| Feb-04-20 08:00AM | Onconova Therapeutics to Present Update at the 2020 BIO CEO & Investor Conference in New York City GlobeNewswire +19.02% |
| Jan-23-20 05:44PM | Onconova shares rise after company regains rights to drug in China American City Business Journals +9.12% |
| 08:30AM | Onconova Therapeutics Regains Rigosertib Rights in Greater China GlobeNewswire |
| Jan-03-20 01:27PM | Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market GlobeNewswire +16.74% |
| Jan-02-20 01:48PM | Bucks County biopharm firm plans $10M stock sale American City Business Journals +8.85% |
| Dec-31-19 11:30AM | Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market GlobeNewswire -20.08% |
| Dec-23-19 07:33PM | Onconova Therapeutics, Inc. (ONTX) Is Burning These Hedge Funds Insider Monkey |
| Dec-19-19 01:44PM | Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market GlobeNewswire |
| Dec-18-19 09:05AM | Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -8.34% |
| 09:00AM | Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand GlobeNewswire |
| Dec-17-19 07:30AM | Onconova Therapeutics and Pint Pharma Announce Brazilian Health Authority Approval for Initiating INSPIRE Trial with Intravenous Rigosertib in Higher-Risk Myelodysplastic Syndromes in Brazil GlobeNewswire |
| Dec-10-19 03:07PM | Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-Market GlobeNewswire |
| Dec-09-19 09:00AM | Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual Meeting GlobeNewswire |
| 08:00AM | Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market GlobeNewswire |
| Dec-07-19 08:35AM | The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga |
| Dec-06-19 08:49AM | Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 6, 2019: TSLA, ONTX, XHB, BIG, SFIX Benzinga +19.82% |
| 07:30AM | Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US GlobeNewswire |
| Nov-25-19 09:26AM | Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering GlobeNewswire -9.27% |
| Nov-22-19 02:46PM | Bucks County biopharm firm enters into licensing deal, embarks on stock sale American City Business Journals -5.80% |
| Nov-21-19 11:23AM | Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering GlobeNewswire -45.71% |
| 10:16AM | Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada GlobeNewswire |
| Nov-07-19 07:30AM | Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition GlobeNewswire -9.50% |
| Oct-24-19 07:30AM | Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update GlobeNewswire -9.35% |
| Sep-24-19 10:15AM | Bucks County biopharm firm opts for private over public stock sale American City Business Journals |
| Sep-23-19 08:52AM | Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock GlobeNewswire -28.13% |
| Sep-19-19 07:39AM | The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO Benzinga -5.11% |
| Sep-18-19 10:05AM | Onconova Therapeutics Announces Termination of Proposed Public Offering GlobeNewswire |
| Sep-16-19 07:30AM | Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit GlobeNewswire -15.00% |
| Aug-23-19 01:23PM | Edited Transcript of ONTX earnings conference call or presentation 14-Aug-19 1:00pm GMT Thomson Reuters StreetEvents |
| Aug-14-19 07:30AM | Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results GlobeNewswire |
| Aug-12-19 07:30AM | Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics GlobeNewswire |
| Aug-07-19 07:30AM | Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2019 Financial Results GlobeNewswire |
| Aug-06-19 10:30AM | Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks |
| Jun-10-19 07:30AM | Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association GlobeNewswire |
| May-30-19 06:26PM | Edited Transcript of ONTX earnings conference call or presentation 14-May-19 1:00pm GMT Thomson Reuters StreetEvents |
| May-28-19 07:30AM | Onconova Therapeutics Announces Presentations at Three Upcoming Conferences GlobeNewswire |
| May-14-19 07:30AM | Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results GlobeNewswire |
| May-13-19 12:52PM | Newtown biopharm firm could reap $50M from Chinese licensing deal American City Business Journals |
| 07:30AM | Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China GlobeNewswire |
| May-07-19 07:30AM | Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2019 Financial Results GlobeNewswire |
| May-06-19 07:30AM | Onconova Therapeutics Announces Presentations at the 15th International Symposium on Myelodysplastic Syndromes (MDS 2019) in Copenhagen, Denmark GlobeNewswire |
| Apr-02-19 07:30AM | Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9 GlobeNewswire +9.17% |
| 02:36AM | Edited Transcript of ONTX earnings conference call or presentation 26-Mar-19 1:00pm GMT Thomson Reuters StreetEvents |
| Mar-26-19 07:30AM | Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results GlobeNewswire -10.41% |
| Mar-25-19 07:30AM | Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes GlobeNewswire |
| Mar-19-19 07:30AM | Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results GlobeNewswire |
| Mar-12-19 07:30AM | Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA GlobeNewswire |
| Feb-04-19 08:00AM | Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City GlobeNewswire |
| Jan-31-19 07:30AM | Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City GlobeNewswire +27.05% |
| Jan-22-19 07:30AM | Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL GlobeNewswire |
| Jan-16-19 01:08PM | Bucks County biopharm firm names new CEO American City Business Journals -8.90% |
| Jan-15-19 05:15PM | Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer GlobeNewswire |
| Jan-02-19 07:30AM | Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS) GlobeNewswire +15.17% |
| Dec-31-18 07:30AM | Onconova to Meet Investors and Potential Partners at China Focus and the 37th Annual J.P. Morgan Healthcare Conferences in San Francisco GlobeNewswire |
| Dec-10-18 07:30AM | Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel GlobeNewswire |
| Dec-03-18 07:30AM | Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting GlobeNewswire |
| Nov-16-18 01:47PM | Edited Transcript of ONTX earnings conference call or presentation 13-Nov-18 2:00pm GMT Thomson Reuters StreetEvents |
| Nov-13-18 07:00AM | Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018 GlobeNewswire -18.20% |
| Nov-07-18 08:30AM | Onconova Welcomes Richard (Ric) Woodman, M.D., as Chief Medical Officer (CMO) GlobeNewswire |
| Nov-06-18 10:30AM | Onconova Therapeutics (ONTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks |
| Nov-05-18 08:30AM | Onconova Announces Four Presentations from Rigosertib Clinical Trials in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting & Exposition GlobeNewswire |
| Nov-01-18 08:30AM | Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2018 Financial Results GlobeNewswire +8.56% |
| Oct-29-18 08:30AM | Onconova Therapeutics to Meet with Potential Investors and Business Development Partners at the Bio-Europe 24th Annual International Partnering Conference in Copenhagen, Denmark GlobeNewswire |
| Oct-17-18 08:30AM | Onconova Therapeutics Announces Issuance of a New U.S. Patent for Rigosertib GlobeNewswire |
| Oct-10-18 08:30AM | Onconova Therapeutics to Present Update at the 2018 BIO Investor Forum in San Francisco GlobeNewswire |
| Sep-27-18 08:00AM | Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences ACCESSWIRE -11.77% |
| Sep-26-18 12:12PM | Bucks County biopharm firm implements reverse stock split American City Business Journals |
| Sep-25-18 09:16AM | Onconova Therapeutics Announces Reverse Stock Split GlobeNewswire |
| Aug-21-18 09:46AM | Edited Transcript of ONTX earnings conference call or presentation 14-Aug-18 1:00pm GMT Thomson Reuters StreetEvents +6.10% |
| 08:30AM | Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma GlobeNewswire |
| Aug-14-18 08:00AM | Onconova Therapeutics Reports Business Highlights and Financial Results for Second Quarter 2018 GlobeNewswire -9.73% |
| 07:00AM | Onconova Therapeutics Inc. to Host Earnings Call ACCESSWIRE |
| Aug-07-18 08:00AM | Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2018 Financial Results GlobeNewswire |
| Jul-17-18 07:25AM | Free Technical Research on OPKO Health and Three More Biotech Equities ACCESSWIRE |
| Jun-21-18 08:00AM | Onconova Therapeutics Announces Promotion for Steven M. Fruchtman, M.D. GlobeNewswire |
| Jun-07-18 08:30AM | Onconova Therapeutics Announces Presentation at the 23rd Congress of the European Hematology Association GlobeNewswire +41.48% |
| May-29-18 08:00AM | Onconova Therapeutics, Inc. to Present at the 8th Annual LD Micro Invitational ACCESSWIRE +10.40% |
| May-25-18 07:21PM | Who Are The Top Investors In Onconova Therapeutics Inc (NASDAQ:ONTX)? Simply Wall St. |
| May-22-18 07:00AM | Free Technical Insights on OPKO Health and Three Other Biotech Stocks ACCESSWIRE |
| May-16-18 08:20PM | Edited Transcript of ONTX earnings conference call or presentation 15-May-18 1:00pm GMT Thomson Reuters StreetEvents |
| May-15-18 08:30AM | Onconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018 GlobeNewswire -6.64% |
| 07:31AM | Analysts Expect Breakeven For Onconova Therapeutics Inc (NASDAQ:ONTX) Simply Wall St. |
| May-09-18 08:30AM | Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2018 Financial Results GlobeNewswire |
| May-03-18 08:00AM | Onconova Therapeutics to Present at the Disruptive Growth and Healthcare Conference on May 8th, 2018 GlobeNewswire |
| May-01-18 08:10PM | Onconova Therapeutics Inc (NASDAQ:ONTX): Does The Earnings Decline Make It An Underperformer? Simply Wall St. |
| 06:33PM | Onconova Therapeutics Announces Closing of $28.75 Million Upsized Underwritten Public Offering GlobeNewswire |
| Apr-27-18 06:00AM | Onconova Therapeutics Announces Pricing of $25.0 Million Upsized Underwritten Public Offering GlobeNewswire -7.24% |
| Apr-19-18 08:30AM | Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting GlobeNewswire |
|
|
|
|
| Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; a license and collaboration agreement with HanX Biopharmaceuticals, Inc.; and a collaboration agreement with Inceptua Medicines Access for a pre-approval access program related to intravenous rigosertib. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Reddy E Premkumar | Director | Nov 25 | Buy | 0.20 | 500,000 | 100,000 | 544,546 | Nov 26 07:57 AM | | MARINO JAMES J | Director | Nov 25 | Buy | 0.20 | 150,000 | 30,000 | 166,942 | Nov 26 07:53 AM | | Fruchtman Steven M | President, Chief Executive Off | Nov 25 | Buy | 0.20 | 149,000 | 29,800 | 149,426 | Nov 26 07:51 AM | | Guerin Mark Patrick | Chief Financial Officer | Nov 25 | Buy | 0.20 | 87,500 | 17,500 | 87,844 | Nov 26 07:50 AM | | OLER ABRAHAM N. | VP Corp Dev & Gen Counsel | Nov 25 | Buy | 0.20 | 75,000 | 15,000 | 75,000 | Nov 26 07:46 AM | | MEHTA VIREN | Director | Nov 25 | Buy | 0.20 | 250,000 | 50,000 | 250,857 | Nov 27 08:33 AM | | MARINO JAMES J | Director | Sep 25 | Buy | 1.60 | 7,260 | 11,616 | 16,942 | Sep 26 06:22 PM | | TYNDALL CAPITAL PARTNERS L P | 10% Owner | Sep 24 | Sale | 1.19 | 16,700 | 19,873 | 616,389 | Sep 26 04:16 PM | | ARMISTICE CAPITAL, LLC | 10% Owner | Sep 23 | Sale | 1.27 | 10,249 | 13,016 | 816,702 | Sep 25 05:41 PM | | TYNDALL CAPITAL PARTNERS L P | 10% Owner | Sep 23 | Sale | 1.23 | 37,242 | 45,968 | 633,089 | Sep 24 04:08 PM | | TYNDALL CAPITAL PARTNERS L P | 10% Owner | Sep 20 | Sale | 1.62 | 75,119 | 121,430 | 670,331 | Sep 24 04:08 PM | | TYNDALL CAPITAL PARTNERS L P | 10% Owner | Sep 18 | Sale | 2.10 | 49,995 | 105,014 | 745,450 | Sep 20 04:05 PM | | 683 Capital Management, LLC | Former 10% Owner | Sep 18 | Sale | 2.03 | 506,877 | 1,030,684 | 460,000 | Sep 20 03:21 PM | | TYNDALL CAPITAL PARTNERS L P | 10% Owner | Sep 11 | Sale | 2.75 | 1,247 | 3,432 | 795,445 | Sep 13 04:24 PM | | TYNDALL CAPITAL PARTNERS L P | 10% Owner | Sep 09 | Sale | 2.77 | 400 | 1,106 | 796,692 | Sep 11 04:16 PM | | TYNDALL CAPITAL PARTNERS L P | 10% Owner | Sep 06 | Sale | 2.78 | 5,015 | 13,954 | 797,092 | Sep 09 04:10 PM | | TYNDALL CAPITAL PARTNERS L P | 10% Owner | Sep 05 | Sale | 2.75 | 400 | 1,100 | 802,107 | Sep 09 04:10 PM | | TYNDALL CAPITAL PARTNERS L P | 10% Owner | Jul 10 | Sale | 2.81 | 2,742 | 7,697 | 802,507 | Jul 11 04:43 PM | | TYNDALL CAPITAL PARTNERS L P | 10% Owner | Jul 09 | Sale | 2.84 | 8,185 | 23,204 | 805,249 | Jul 11 04:43 PM | | TYNDALL CAPITAL PARTNERS L P | 10% Owner | Jun 27 | Sale | 3.45 | 1,458 | 5,025 | 813,434 | Jul 01 04:35 PM | | TYNDALL CAPITAL PARTNERS L P | 10% Owner | Jun 25 | Sale | 3.40 | 1,380 | 4,689 | 814,892 | Jun 27 04:21 PM |
|
|
|
|
|
|
